Novo Nordisk A/S , the Danish pharma that specializes in diabetes drugs, does not want to grow in China through M&A. It plans to continue its emphasis on developing its own innovative drugs. To that end, Novo Nordisk has previously announced investments in its Beijing R&D center and Tianjin manufacturing plant, while it is also working to increase diabetes education in China. More details....

Stock Symbol: (NYSE: NVO)     Share this with colleagues: